Corrigendum to "Protective effect of creatine against RNA damage" [Mutat. Res. 670 (2009) 59-67] (DOI:10.1016/j.mrfmmm.2009.07.005);Protective effect of creatine against RNA damage

Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis

Volumn 670, Issue 1-2, 2009, Pages 59-67

  Fimognari, Carmela ^a   Sestili, Piero ^b   Lenzi, Monia ^a   Cantelli Forti, Giorgio ^a   Hrelia, Patrizia ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b UNIVERSITY OF URBINO   (Italy)

Author keywords

Creatine; Doxorubicin; Human T leukemia cells; Reactive nitrogen species; Reactive oxygen species; RNA damage

Indexed keywords

ADENOSINE TRIPHOSPHATE; CREATINE; CREATINE PHOSPHATE; DNA; DOXORUBICIN; FREE RADICAL; HYDROGEN PEROXIDE; MESYLIC ACID ETHYL ESTER; N ACETYL S NITROSOPENICILLAMINE; NUCLEOPHILE; RNA; SPERMINE; XENOBIOTIC AGENT;

ALZHEIMER DISEASE; ARTICLE; ATHEROSCLEROTIC PLAQUE; CELL FUNCTION; CONTROLLED STUDY; DEGENERATIVE DISEASE; DNA DAMAGE; ELECTROPHILIC STRESS; GENETIC DAMAGE; HUMAN; HUMAN CELL; MAMMARY ARTERY; OXIDATIVE STRESS; PRIORITY JOURNAL; RNA DAMAGE;

EID: 70350004700     PISSN: 00275107     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mrfmmm.2010.02.002     Document Type: Erratum

References (63)

1. De Flora S., Izzotti A., D'Agostini F., Balansky R.M., Noonan D., and Albini A. Multiple points of intervention in the prevention of cancer and other mutation-related diseases. Mutat. Res. 480-481 (2001) 9-22
2. Castellani R.J., Nunomura A., Rolston R.K., Moreira P.I., Takeda A., Perry G., and Smith M.A. Sublethal RNA oxidation as a mechanism for neurodegenerative disease. Int. J. Mol. Sci. 9 (2008) 789-806
3. Nunomura A., Perry G., Pappolla M.A., Wade R., Hirai K., Chiba S., and Smith M.A. RNA oxidation is a prominent feature of vulnerable neurons in Alzheimer's disease. J. Neurosci. 19 (1999) 1959-1964
4. Cao X., Yeo G., Muotri A.R., Kuwabara T., and Gage F.H. Noncoding RNAs in the mammalian central nervous system. Annu. Rev. Neurosci. 29 (2006) 77-103
5. Costa F.F. Non-coding RNAs: new players in eukaryotic biology. Gene 357 (2005) 83-94
6. Mehler M.F., and Mattick J.S. Non-coding RNAs in the nervous system. J. Physiol. 575 (2006) 333-341
7. Hofer T., Marzetti E., Xu J., Seo A.Y., Gulec S., Knutson M.D., Leeuwenburgh C., and Dupont-Versteegden E.E. Increased iron content and RNA oxidative damage in skeletal muscle with aging and disuse atrophy. Exp. Gerontol. 43 (2008) 563-570
8. Martinet W., De Meyer G.R.Y., Herman A.G., and Kockx M.M. Reactive oxygen species induce RNA damage in human atherosclerosis. Eur. J. Clin. Invest. 34 (2004) 323-327
9. Martinet W., De Meyer G.R.Y., Herman A.G., and Kockx M.M. RNA damage in human atherosclerosis. RNA Biol. 2 (2005) 4-7
10. Nunomura A., Honda K., Takeda A., Hirai K., Zhu X., Smith M.A., and Perry G. Oxidative damage to RNA in neurodegenerative diseases. J. Biomed. Biotechnol. 2006 (2006) 1-6
11. Nunomura A., Castellani R.J., Zhu X., Moreira P.I., Perry G., and Smith M.A. Involvement of oxidative stress in Alzheimer disease. J. Neuropathol. Exp. Neurol. 65 (2006) 631-641
12. Nunomura A., Moreira P.I., Takeda A., Smith M.A., and Perry G. Oxidative RNA damage and neurodegeneration. Curr. Med. Chem. 14 (2007) 2968-2975
13. Tateyama M., Takeda A., Onodera Y., Matsuzaki M., Hasegawa T., Nunomura A., Hirai K., Perry G., Smith M.A., and Itoyama Y. Oxidative stress and predominant Abeta42(43) deposition in myopathies with rimmed vacuoles. Acta Neuropathol. (Berl.) 105 (2003) 581-585
14. Honda K., Smith M.A., Zhu X., Baus D., Merrick W.C., Tartakoff A.M., Hattier T., Harris P.L., Siedlak S.L., Fujioka H., Liu Q., Moreira P.I., Miller F.P., Nunomura A., Shimohama S., and Perry G. Ribosomal RNA in Alzheimer disease is oxidized by bound redox-active iron. J. Biol. Chem. 280 (2005) 20978-20986
15. Tanaka M., Chock P.B., and Stadtman E.R. Oxidized messenger RNA induces translation errors. Proc. Natl. Acad. Sci. U.S.A. 104 (2007) 66-71
16. Sestili P., Martinelli C., Bravi G., Piccoli G., Curci R., Battistelli M., Falcieri E., Agostini D., Gioacchini A.M., and Stocchi V. Creatine supplementation affords cytoprotection in oxidatively injured cultured mammalian cells via direct antioxidant activity. Free Radic. Biol. Med. 40 (2006) 837-849
17. Guidi C., Potenza L., Sestili P., Martinelli C., Guescini M., Stocchi L., Zeppa S., Polidori E., Annibalini G., and Stocchi V. Differential effect of creatine on oxidatively-injured mitochondrial and nuclear DNA. Biochim. Biophys. Acta 1780 (2008) 16-26
18. Hofer T., Badouard C., Bajak E., Ravanat J.L., Mattsson A., and Cotgreave I.A. Hydrogen peroxide causes greater oxidation in cellular RNA than in DNA. Biol. Chem. 386 (2005) 333-337
19. Fimognari C., Sestili P., Lenzi M., Bucchini A., Cantelli-Forti G., and Hrelia P. RNA as a new target for toxic and protective agents. Mutat. Res. 648 (2008) 15-22
20. Mueller O., Hahnenberger K., Dittmann M., Yee H., Dubrow R., Nagle R., and Isley D.D. A microfluidic system for high-speed reproducible DNA sizing and quantitation. Electrophoresis 21 (2000) 128-134
21. Schroeder A., Mueller O., Stocker S., Salowsky R., Leiber M., Gassmann M., Lightfoot S., Menzel W., Granzow M., and Ragg T. The RIN: an RNA integrity number for assigning integrity values to RNA measurements. BMC Mol. Biol. 7 (2006) 3
22. Kirsch-Volders M., Sofuni T., Albertini S., Eastmond D., Fenech M., Ishidate Jr. M., Kirchner S., Lorge E., Morita T., Norppa H., Surralés J., Vanhauwaert A., and Wakata A. Report from the in vitro micronucleus assay working group. Mutat. Res. 540 (2003) 153-163
23. Walker J.B. Creatine: biosynthesis, regulation, and function. Adv. Enzymol. Relat. Areas Mol. Biol. 50 (1979) 177-242
24. Wallimann T., Wyss M., Brdiczka D., Nicolay K., and Eppenberger H.M. Intracellular compartmentation, structure and function of creatine kinase isoenzymes in tissues with high and fluctuating energy demands: the "phosphocreatine circuit" for cellular energy homeostasis. Biochem. J. 281 (1992) 21-40
25. Persky A.M., and Brazeau G.A. Clinical pharmacology of dietary supplement Cr monohydrate. Pharmacol. Rev. 53 (2001) 161-176
26. Kasparova S., Brezova V., Valko M., Horecky J., Mlynarik V., Liptaj T., Vancova O., Ulicna O., and Dobrota D. Study of the oxidative stress in a rat model of chronic brain hypoperfusion. Neurochem. Int. 46 (2005) 601-611
27. Kasparova S., Dobrota D., Mlynarik V., Pham T.N., Liptaj T., Horecky J., Braunova Z., and Gvozdjakova A. A study of creatine kinase reaction in rat brain under chronic pathological conditions-chronic ischemia and ethanol intoxication. Brain Res. Bull. 53 (2000) 431-435
28. Wyss M., and Schulze A. Health implications of creatine: can oral creatine supplementation protect against neurological and atherosclerotic disease?. Neuroscience 112 (2002) 243-260
29. Pearlman J.P., and Fielding R.A. Creatine monohydrate as a therapeutic aid in muscular dystrophy. Nutr. Rev. 64 (2006) 80-88
30. Lawler J.M., Barnes W.S., Wu G., Song W., and Demaree S. Direct antioxidant properties of creatine. Biochem. Biophys. Res. Commun. 290 (2002) 47-52
31. P. Sestili, E. Barbieri, C. Martinelli, M. Battistelli, M. Guescini, V. Vallorani, L. Casadei, A. D'Emilio, E. Falcieri, G. Piccoli, D. Agostini, G. Annibalini, M. Paolillo, A.M. Gioacchini, V. Stocchi, Creatine supplementation prevents the inhibition of myogenic differentiation in oxidatively injured C2C12 murine myoblasts, Mol. Nutr. Food Res., in press.
32. Singal P.K., Iliskovic N., Li T., and Kumar D. Adriamycin cardiomyopathy: pathophysiology and prevention. FASEB J. 11 (1997) 931-936
33. Minotti G., Cairo G., and Monti E. Role of iron in anthracycline cardiotoxicity: new tunes for an old song?. FASEB J. 13 (1999) 199-212
34. Arola O.J., Saraste A., Pulkki K., Kallajoki M., Parvinen M., and Voipio-Pulkki L.M. Acute doxorubicin cardiotoxicity involves cardiomyocyte apoptosis. Cancer Res. 60 (2000) 1789-1792
35. Horenstein M.S., Vander Heide R.S., and L'Ecuyer T.J. Molecular basis of anthracycline-induced cardiotoxicity and its prevention. Mol. Genet. Metab. 71 (2000) 436-444
36. DeAtley S.M., Aksenov M.Y., Aksenova M.V., Jordan B., Carney J.M., and Butterfield D.A. Adriamycin-induced changes of creatine kinase activity in vivo and in cardiomyocyte culture. Toxicology 134 (1999) 51-62
37. Miura T., Muraoka S., and Fujimoto Y. Inactivation of creatine kinase by adriamycin during interaction with horseradish peroxidase. Biochem. Pharmacol. 60 (2000) 95-99
38. Olson R.D., and Mushlin P.S. Doxorubicin cardiotoxicity: analysis of prevailing hypotheses. FASEB J. 4 (1990) 3076-3086
39. Cheneval D., Carafoli E., Powell G.L., and Marsh D. A spin-label electron spin resonance study of the binding of mitochondrial creatine kinase to cardiolipin. Eur. J. Biochem. 186 (1989) 415-419
40. 3+-induced inactivation of rat heart mitochondrial creatine kinase: sensitivity to lipid peroxidation. Biol. Pharm. Bull. 17 (1994) 1220-1223
41. Stachowiak O., Dolder M., Wallimann T., and Richter C. Mitochondrial creatine kinase is a prime target of peroxynitrite-induced modification and inactivation. J. Biol. Chem. 273 (1998) 16694-16699
42. b-CK). Biochem. J. 344 (1999) 413-417
43. Weinstein D.M., Mihm M.J., and Bauer J.A. Cardiac peroxynitrite formation and left ventricular dysfunction following doxorubicin treatment in mice. J. Pharmacol. Exp. Ther. 294 (2000) 396-401
44. Tokarska-Schlattner M., Wallimann T., and Schlattner U. Multiple interference of anthracyclines with mitochondrial creatine kinases: preferential damage of the cardiac isoenzyme and its implications for drug cardiotoxicity. Mol. Pharmacol. 61 (2002) 516-523
45. Furter R., Furter-Graves E.M., and Wallimann T. Creatine kinase: the reactive cysteine is required for synergism but is nonessential for catalysis. Biochemistry 32 (1993) 7022-7029
46. Feng W., Liu G., Xia R., Abramson J.J., and Pessah I.N. Site-selective modification of hyperreactive cysteines of ryanodine receptor complex by quinones. Mol. Pharmacol. 55 (1999) 821-831
47. Bolton J.L., Trush M.A., Penning T.M., Dryhurst G., and Monks T.J. Role of quinones in toxicology. Chem. Res. Toxicol. 13 (2000) 135-160
48. Santos R.V., Batista Jr. M.L., Caperuto E.C., and Costa Rosa L.F. Chronic supplementation of creatine and vitamins C and E increases survival and improves biochemical parameters after doxorubicin treatment in rats. Clin. Exp. Pharmacol. Physiol. 34 (2007) 1294-1299
49. Tokarska-Schlattner M., Dolder M., Gerber I., Speer O., Wallimann T., and Schlattner U. Reduced creatine-stimulated respiration in doxorubicin challenged mitochondria: particular sensitivity of the heart. Biochim. Biophys. Acta 1767 (2007) 1276-1284
50. Arstall M.A., Bailey C., Gross W.L., Bak M., Balligand J.L., and Kelly R.A. Reversible S-nitrosation of creatine kinase by nitric oxide in adult rat ventricular myocytes. J. Mol. Cell. Cardiol. 30 (1998) 979-988
51. Wolosker H., Panizzutti R., and Engelender S. Inhibition of creatine kinase by S-nitrosoglutathione. FEBS Lett. 392 (1996) 274-276
52. Vorgerd M., Grehl T., Jager M., Muller K., Freitag G., Patzold T., Bruns N., Fabian K., Tegenthoff M., Mortier W., Luttmann A., Zange J., and Malin J.P. Creatine therapy in myophosphorylase deficiency (McArdle disease): a placebo-controlled crossover trial. Arch. Neurol. 57 (2000) 956-963
53. 31P magnetic resonance spectroscopy study. Neurol. Res. 22 (2000) 145-150
54. Tarnopolsky M.A., Mahoney D.J., Vajsar J., Rodriguez C., Doherty T.J., Roy B.D., and Biggar D. Creatine monohydrate enhances strength and body composition in Duchenne muscular dystrophy. Neurology 62 (2004) 1771-1777
55. Matthews R.T., Ferrante R.J., Klivenyi P., Yang L., Klein A.M., Mueller G., Kaddurah-Daouk R., and Beal M.F. Creatine and cyclocreatine attenuate MPTP neurotoxicity. Exp. Neurol. 157 (1999) 142-149
56. Holtzman D., Khait I., Mulkern R., Allred E., Rand T., Jensen F., and Kraft R. In vivo development of brain phosphocreatine in normal and creatine-treated rabbit pups. J. Neurochem. 73 (1999) 2477-2484
57. Neubauer S., Remkes H., Spindler M., Horn M., Wiesmann F., Prestle J., Walzel B., Ertl G., Hasenfuss G., and Wallimann T. Downregulation of the Na(+)-creatine cotransporter in failing human myocardium and in experimental heart failure. Circulation 100 (1999) 1847-1850
58. Gordon A., Hultman E., Kaijser L., Kristjansson S., Rolf C.J., Nyquist O., and Sylven C. Creatine supplementation in chronic heart failure increases skeletal muscle creatine phosphate and muscle performance. Cardiovasc. Res. 30 (1995) 413-418
59. Adhihetty P.J., and Beal M.F. Creatine and its potential therapeutic value for targeting cellular energy impairment in neurodegenerative diseases. Neuromol. Med. 10 (2008) 275-290
60. Deminice R., Portari G.V., Vannucchi H., and Jordao A.A. Effects of creatine supplementation on homocysteine levels and lipid peroxidation in rats. Br. J. Nutr. 15 (2008) 1-7
61. Bender A., Samtleben W., Elstner M., and Klopstock T. Long-term creatine supplementation is safe in aged patients with Parkinson disease. Nutr. Res. 28 (2008) 172-178
62. Johnston A.P., Burke D.G., MacNeil L.G., and Candow D.G. Effect of creatine supplementation during cast-induced immobilization on the preservation of muscle mass, strength, and endurance. J. Strength Condit. Res. 23 (2009) 116-120
63. B. Gualano, G.G. Artioli, J.R. Poortmans, A.H. Lancha Jr., Exploring the therapeutic role of creatine supplementation, Amino Acids, in press.